Galmed Pharmaceuticals Ltd. (GLMD) Stock Score, Valuation & Financial Research

Galmed Pharmaceuticals Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GLMD

Galmed Pharmaceuticals Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 4.63. These figures are a research snapshot, not a buy or sell recommendation.

What Galmed Pharmaceuticals Ltd. does

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and strategic financing to fund the research and development of its lead drug candidate, Aramchol, for liver, cardiometabolic, and GI oncological indications.

Products and services

  • The company is focused on the development of Aramchol, a synthetic fatty acid/bile acid conjugate, for the treatment of various liver, cardiometabolic, and GI oncological diseases.

Brands and product families

  • Aramchol — Lead drug candidate for liver and cardiometabolic diseases. Source

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various third-party CROs to conduct clinical trials and provide research services; specific supplier names are not disclosed. Source
  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party manufacturers for the production of its drug candidates; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various entities developing therapies for NASH, fibrosis, and other liver or cardiometabolic diseases, though specific competitors are not named in the filing. Source

Business strengths to evaluate

  • Proprietary development of Aramchol Source

Business risks and research considerations

  • Going concern uncertainty due to recurring losses and limited capital Source
  • Dependence on clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GLMD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.63
Market capitalization:
4.78M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -11.34M
Free cash flow:
USD -6.32M
Cash:
USD 3.04M
Total debt:
USD 129K
EPS:
USD -13.82

What stands out

  • Free cash flow is USD -6.32M, negative for the stored period.
  • The balance sheet shows USD 3.04M of cash versus USD 129K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.92M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GLMD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GLMD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is GLMD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for GLMD to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of GLMD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research GLMD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.